![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Diabetic Gastroparesis Candidate Fails in Phase 3
Diabetic Gastroparesis Candidate Fails in Phase 3
July 26, 2016
Evoke Pharma’s drug candidate EVK-001 sunk in a Phase 3 trial assessing its use in female patients with symptomatic diabetic gastroparesis.
The candidate failed to meet its primary endpoint of symptom improvement at week four, the California-based company said.
The company said that data from multiple clinical sites revealed patient improvement, but this was not consistent among all study locations.
Upcoming Events
-
21Oct